《大行報告》瑞銀下調君實生物(01877.HK)目標價至70.9元 評級「買入」
瑞銀髮表評級報告,指君實生物(01877.HK)前日(23日)公佈口服藥VV116在一項對比Paxlovid用於輕至中度新冠病毒感染的早期治療第三期註冊臨牀研究,已達到方案預設的主要終點,公司將於近期與監管部門溝通,並遞交新藥上市申請事宜。
該行表示,考慮到近期內地疫情反彈,預料公司很快會得到反饋,估計該藥物銷售峯值約10億元人民幣。該行引述管理層透露VV116的其他臨牀測試亦順利進行,當公司獲得烏茲別克的批準後,該行預料,公司即將公佈有利的潛在數據有助VV116銷售拓展至全球。
瑞銀調整估值模型,以反映市場波動性,並將君實生物目標價由77.7元下調至70.9元,維持「買入」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.